1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19697
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKonitsiotis, S.en
dc.date.accessioned2015-11-24T19:01:29Z-
dc.date.available2015-11-24T19:01:29Z-
dc.identifier.issn1744-7658-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19697-
dc.rightsDefault Licence-
dc.subjectAdministration, Cutaneousen
dc.subjectAnimalsen
dc.subjectAntiparkinson Agents/*administration & dosageen
dc.subjectBrain/drug effects/metabolismen
dc.subjectCatechol O-Methyltransferase/antagonists & inhibitors/metabolismen
dc.subjectCatechols/pharmacologyen
dc.subjectClinical Trials as Topicen
dc.subjectDopamine Agonists/*administration & dosageen
dc.subject*Drug Delivery Systemsen
dc.subjectDrug Therapy, Combinationen
dc.subjectEnzyme Inhibitors/pharmacologyen
dc.subjectHumansen
dc.subjectIndans/pharmacologyen
dc.subjectLevodopa/*administration & dosageen
dc.subjectLiposomesen
dc.subjectMonoamine Oxidase Inhibitors/pharmacologyen
dc.subjectMotor Neurons/*drug effects/enzymologyen
dc.subjectMovement Disorders/drug therapy/metabolismen
dc.subjectNitrilesen
dc.subjectParkinson Disease/drug therapy/metabolismen
dc.subjectReceptors, Glutamate/drug effects/metabolismen
dc.subjectSignal Transduction/drug effectsen
dc.titleNovel pharmacological strategies for motor complications in Parkinson's diseaseen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1517/13543784.14.4.377-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15882115-
heal.identifier.secondaryhttp://informahealthcare.com/doi/abs/10.1517/13543784.14.4.377-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2005-
heal.abstractIn advanced Parkinson's disease, the combination of disease progression and levodopa therapy leads to the development of motor problems complicating the therapeutic response, known as motor response complications. The nonphysiological, pulsatile stimulation produced by most currently available dopaminergic therapies triggers a complicated series of responses resulting in the dysregulation of glutamate receptors and many other neurotransmitter systems on striatal neurons. Although a number of novel compounds that provide a more continuous dopaminergic stimulation are becoming available, no practical way to accomplish this in a truly physiological manner currently exists. Novel strategies for pharmacological intervention with the use of nondopaminergic treatments, with drugs targeting selected transmitter receptors expressed on striatal neurons appear more promising. These include NMDA or AMPA antagonists, or drugs acting on 5-hydroxytryptamine subtype 2A, alpha2-adrenergic, adenosine A2A and cannabinoid CB1 receptors. Future strategies may also target pre- and postsynaptic components that regulate firing pattern, like synaptic vesicle proteins, or nonsynaptic gap junction communication mechanisms, or drugs with actions at the signal transduction systems that modulate the phosphorylation state of NMDA receptors. These new therapeutic strategies, alone or in combination, hold the promise of providing effective control or reversal of motor response complications.en
heal.journalNameExpert Opin Investig Drugsen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons